Cargando…

Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients

The knowledge on how gut microbes contribute to the inflammatory bowel disease (IBD) at the onset of disease is still scarce. We compared gut microbiota in newly diagnosed, treatment-naïve adult IBD (Crohn’s disease (CD) and ulcerative colitis (UC)) to irritable bowel syndrome (IBS) patients and hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Čipčić Paljetak, Hana, Barešić, Anja, Panek, Marina, Perić, Mihaela, Matijašić, Mario, Lojkić, Ivana, Barišić, Ana, Vranešić Bender, Darija, Ljubas Kelečić, Dina, Brinar, Marko, Kalauz, Mirjana, Miličević, Marija, Grgić, Dora, Turk, Nikša, Karas, Irena, Čuković-Čavka, Silvija, Krznarić, Željko, Verbanac, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196785/
https://www.ncbi.nlm.nih.gov/pubmed/35695669
http://dx.doi.org/10.1080/19490976.2022.2083419
_version_ 1784727262756601856
author Čipčić Paljetak, Hana
Barešić, Anja
Panek, Marina
Perić, Mihaela
Matijašić, Mario
Lojkić, Ivana
Barišić, Ana
Vranešić Bender, Darija
Ljubas Kelečić, Dina
Brinar, Marko
Kalauz, Mirjana
Miličević, Marija
Grgić, Dora
Turk, Nikša
Karas, Irena
Čuković-Čavka, Silvija
Krznarić, Željko
Verbanac, Donatella
author_facet Čipčić Paljetak, Hana
Barešić, Anja
Panek, Marina
Perić, Mihaela
Matijašić, Mario
Lojkić, Ivana
Barišić, Ana
Vranešić Bender, Darija
Ljubas Kelečić, Dina
Brinar, Marko
Kalauz, Mirjana
Miličević, Marija
Grgić, Dora
Turk, Nikša
Karas, Irena
Čuković-Čavka, Silvija
Krznarić, Željko
Verbanac, Donatella
author_sort Čipčić Paljetak, Hana
collection PubMed
description The knowledge on how gut microbes contribute to the inflammatory bowel disease (IBD) at the onset of disease is still scarce. We compared gut microbiota in newly diagnosed, treatment-naïve adult IBD (Crohn’s disease (CD) and ulcerative colitis (UC)) to irritable bowel syndrome (IBS) patients and healthy group. Mucosal and fecal microbiota of 49 patients (13 UC, 10 CD, and 26 IBS) before treatment initiation, and fecal microbiota of 12 healthy subjects was characterized by 16S rRNA gene sequencing. Mucosa was sampled at six positions, from terminal ileum to rectum. We demonstrate that mucosal microbiota is spatially homogeneous, cannot be differentiated based on the local inflammation status and yet provides bacterial footprints superior to fecal in discriminating disease phenotypes. IBD groups showed decreased bacterial diversity in mucosa at all taxonomic levels compared to IBS. In CD and UC, Dialister was significantly increased, and expansion of Haemophilus and Propionibacterium characterized UC. Compared to healthy individuals, fecal microbiota of IBD and IBS patients had increased abundance of Proteobacteria, Enterobacteriaceae, in particular. Shift toward reduction of Adlercreutzia and butyrate-producing taxa was found in feces of IBD patients. Microbiota alterations detected in newly diagnosed treatment-naïve adult patients indicate that the microbiota changes are set and detectable at the disease onset and likely have a discerning role in IBD pathophysiology. Our results justify further investigation of the taxa discriminating between disease groups, such as H. parainfluenzae, R. gnavus, Turicibacteriaceae, Dialister, and Adlercreutzia as potential biomarkers of the disease.
format Online
Article
Text
id pubmed-9196785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91967852022-06-15 Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients Čipčić Paljetak, Hana Barešić, Anja Panek, Marina Perić, Mihaela Matijašić, Mario Lojkić, Ivana Barišić, Ana Vranešić Bender, Darija Ljubas Kelečić, Dina Brinar, Marko Kalauz, Mirjana Miličević, Marija Grgić, Dora Turk, Nikša Karas, Irena Čuković-Čavka, Silvija Krznarić, Željko Verbanac, Donatella Gut Microbes Article The knowledge on how gut microbes contribute to the inflammatory bowel disease (IBD) at the onset of disease is still scarce. We compared gut microbiota in newly diagnosed, treatment-naïve adult IBD (Crohn’s disease (CD) and ulcerative colitis (UC)) to irritable bowel syndrome (IBS) patients and healthy group. Mucosal and fecal microbiota of 49 patients (13 UC, 10 CD, and 26 IBS) before treatment initiation, and fecal microbiota of 12 healthy subjects was characterized by 16S rRNA gene sequencing. Mucosa was sampled at six positions, from terminal ileum to rectum. We demonstrate that mucosal microbiota is spatially homogeneous, cannot be differentiated based on the local inflammation status and yet provides bacterial footprints superior to fecal in discriminating disease phenotypes. IBD groups showed decreased bacterial diversity in mucosa at all taxonomic levels compared to IBS. In CD and UC, Dialister was significantly increased, and expansion of Haemophilus and Propionibacterium characterized UC. Compared to healthy individuals, fecal microbiota of IBD and IBS patients had increased abundance of Proteobacteria, Enterobacteriaceae, in particular. Shift toward reduction of Adlercreutzia and butyrate-producing taxa was found in feces of IBD patients. Microbiota alterations detected in newly diagnosed treatment-naïve adult patients indicate that the microbiota changes are set and detectable at the disease onset and likely have a discerning role in IBD pathophysiology. Our results justify further investigation of the taxa discriminating between disease groups, such as H. parainfluenzae, R. gnavus, Turicibacteriaceae, Dialister, and Adlercreutzia as potential biomarkers of the disease. Taylor & Francis 2022-06-13 /pmc/articles/PMC9196785/ /pubmed/35695669 http://dx.doi.org/10.1080/19490976.2022.2083419 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Čipčić Paljetak, Hana
Barešić, Anja
Panek, Marina
Perić, Mihaela
Matijašić, Mario
Lojkić, Ivana
Barišić, Ana
Vranešić Bender, Darija
Ljubas Kelečić, Dina
Brinar, Marko
Kalauz, Mirjana
Miličević, Marija
Grgić, Dora
Turk, Nikša
Karas, Irena
Čuković-Čavka, Silvija
Krznarić, Željko
Verbanac, Donatella
Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients
title Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients
title_full Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients
title_fullStr Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients
title_full_unstemmed Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients
title_short Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients
title_sort gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196785/
https://www.ncbi.nlm.nih.gov/pubmed/35695669
http://dx.doi.org/10.1080/19490976.2022.2083419
work_keys_str_mv AT cipcicpaljetakhana gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT baresicanja gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT panekmarina gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT pericmihaela gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT matijasicmario gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT lojkicivana gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT barisicana gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT vranesicbenderdarija gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT ljubaskelecicdina gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT brinarmarko gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT kalauzmirjana gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT milicevicmarija gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT grgicdora gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT turkniksa gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT karasirena gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT cukoviccavkasilvija gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT krznariczeljko gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients
AT verbanacdonatella gutmicrobiotainmucosaandfecesofnewlydiagnosedtreatmentnaiveadultinflammatoryboweldiseaseandirritablebowelsyndromepatients